<DOC>
	<DOCNO>NCT01251575</DOCNO>
	<brief_summary>This phase II trial study well sirolimus , cyclosporine mycophenolate mofetil work prevent graft-vs-host disease ( GVHD ) patient hematologic malignancy undergo donor peripheral blood stem cell ( PBSC ) transplant . Giving chemotherapy total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving total-body irradiation together sirolimus , cyclosporine , mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Sirolimus , Cyclosporine , Mycophenolate Mofetil Preventing Graft-versus-Host Disease Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether incidence acute GVHD grade II-IV reduce less historical rate 70 % triple-immunosuppressant combination cyclosporine ( CSP ) /mycophenolate mofetil ( MMF ) sirolimus human leukocyte antigen ( HLA ) class I class II mismatch related unrelated donor hematopoietic cell transplantation ( HCT ) use nonmyeloablative conditioning . The evaluation carry separately among class I class II mismatch patient . SECONDARY OBJECTIVES : I . To evaluate incidence non-relapse mortality day 100 . II . To evaluate incidence grade III-IV acute GVHD . OUTLINE : CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -4 -2 . Patients also undergo total-body irradiation day 0 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell transplantation . IMMUNOSUPPRESSION : Patients receive sirolimus orally ( PO ) daily ( QD ) day -3 180 taper day 365 ; cyclosporine PO twice daily ( BID ) day -3 150 taper day 180 ; mycophenolate mofetil PO thrice daily ( TID ) day 0-30 BID day 100 taper day 150 . After completion study treatment , patient follow 6 month every year thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic , T-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Ages &gt; 50 year hematologic malignancy treatable related unrelated HCT Ages = &lt; 50 year age hematologic diseases treatable allogeneic HCT preexist medical condition prior therapy consider high risk regimen relate toxicity associate high dose transplant ( &gt; 40 % risk transplantrelated mortality [ TRM ] ) ; criterion include patient HCTcomorbidity index ( CI ) score &gt; = 1 ; transplant approve inclusion criterion principal investigator collaborate center Fred Hutchinson Cancer Research Center ( FHCRC ) ; child &lt; 12 year must discuss FHCRC principal investigator ( PI ) prior registration Ages = &lt; 50 year age chronic lymphocytic leukemia ( CLL ) Ages = &lt; 50 year age hematologic diseases treatable allogeneic HCT refuse highdose HCT ; transplant must approve inclusion criterion principal investigator collaborate center FHCRC Aggressive nonHodgkin lymphoma ( NHL ) histologies diffuse large B cell NHL : eligible autologous HCT , eligible highdose allogeneic HCT , fail autologous HCT Mantle cell NHL : may treat first complete remission ( CR ) ; ( diagnostic lumbar puncture [ LP ] require pretransplant ) Low grade NHL : &lt; 6 month duration CR course conventional therapy CLL : must either 1 ) fail meet National Cancer Institute ( NCI ) Working Group criteria complete partial response therapy regimen contain fludarabine ( FLU ) ( another nucleoside analog , e.g . cladribine [ 2CDA ] , pentostatin ) experience disease relapse within 12 month complete therapy regimen contain FLU ( another nucleoside analog ) ; 2 ) fail FLUcyclophosphamide ( CY ) Rituximab ( FCR ) combination chemotherapy time point ; 3 ) `` 17p deletion '' cytogenetic abnormality ; patient receive induction chemotherapy could transplant first ( 1st ) CR ; 4 ) patient diagnosis CLL ( small lymphocytic lymphoma ) progress prolymphocytic leukemia ( PLL ) ; 5 ) patient Tcell CLL PLL Hodgkin lymphoma : must receive failed frontline therapy Multiple myeloma : must receive prior chemotherapy ; consolidation chemotherapy autografting prior nonmyeloablative HCT permit Acute myeloid leukemia ( AML ) : must &lt; 5 % marrow blast time transplant Acute lymphocytic leukemia ( ALL ) : must &lt; 5 % marrow blast time transplant Chronic myeloid leukemia ( CML ) : patient chronic phase 1 ( CP1 ) must fail intolerant tyrosine kinase inhibitor ( TKIs ) ; patient beyond CP1 accept &lt; 5 % marrow blast time transplant Myelodysplasia ( MDS ) /myeloproliferative syndrome ( MPS ) : patient must &lt; 5 % marrow blast time transplant Waldenstrom 's macroglobulinemia : must fail 2 course therapy Patients relate unrelated donor best available donor : ) mismatch antigen level single class I locus ( HLAA , B , C ) +/ additional class I mismatch allele level OR mismatch allele level 2 class I loci ( typed molecular level ) OR mismatch antigen allele level class II locus HLADRB1 and/or DQB1 ; must match least one DRB1 allele one DQB1 allele ; b ) likelihood rapid disease progression HLA type result preliminary search donor pool suggest 10/10 HLAA , B , C , DRB1 DQB1 match donor find ; c ) HLAA , B C one locus allelic mismatch donor available DONOR : Related unrelated volunteer donor mismatch recipient within one follow limitation : Mismatch one HLA class I antigen without additional mismatch one HLAclass I allele , match HLADRB1 HLADQ , OR Mismatched two HLA class I alleles , match HLADRB1 HLADQ , OR HLA class I HLAA , B , C allele match donor allow one two DRB1 and/or DQB1 antigen allele mismatch DONOR : HLAmatching must base result high resolution type HLAA , B , C , DRB1 , DQB DONOR : If patient homozygous mismatch HLA class I locus II locus , donor must heterozygous locus one allele must match patient ( i.e. , patient homozygous A*01:01 donor heterozygous A*01:01 , A*02:01 ) ; mismatch consider oneantigen mismatch rejection DONOR : Donors exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; donor exclude flow cytometric B T cell cytotoxic cross match assay positive DONOR : Only filgrastim ( GCSF ) mobilize PBSC permit hematopoietic stem cell ( HSC ) source protocol Patients best available donor mismatch HLA class I class II A positive crossmatch exists donor recipient Patients rapidly progressive intermediate high grade NHL Patients diagnosis chronic myelomonocytic leukemia ( CMML ) Patients refractory anemia excess blast ( RAEB ) 2 receive myelosuppressive chemotherapy i.e . induction chemotherapy Presence circulate leukemic blast ( peripheral blood ) detect standard pathology patient AML , ALL CML Presence &gt; = 5 % circulate leukemic blast ( peripheral blood ) detect standard pathology patient MDS/MPS Central nervous system ( CNS ) involvement disease refractory intrathecal chemotherapy Fertile men woman unwilling use contraceptive 12 month follow treatment Female patient pregnant breastfeed Human immunodeficiency virus ( HIV ) positive patient Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) nonhematologic malignancy ( except nonmelanoma skin cancer ) render evidence disease , great 20 % chance disease recurrence within 5 year ; exclusion apply patient nonhematologic malignancy require therapy Fungal infection radiological progression receipt amphotericin B active triazole great 1 month Patients active bacterial fungal infection unresponsive medical therapy Cardiac ejection fraction &lt; 35 % ( , unable obtain ejection fraction , shorten fraction &lt; 26 % ) ; ejection fraction require patient &gt; 50 year age , history cardiac disease anthracycline exposure ; patient shorten fraction &lt; 26 % may enrol approve cardiologist Corrected diffusion capacity carbon monoxide ( DLCO ) &lt; 40 % , total lung capacity ( TLC ) &lt; 40 % , forced expiratory volume one second ( FEV1 ) &lt; 40 % and/or receive supplementary continuous oxygen The FHCRC PI study must approve enrollment patient pulmonary nodule Patients clinical laboratory evidence liver disease would evaluate cause liver disease , clinical severity term liver function , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evince prolongation prothrombin time , ascites related portal hypertension , bridge fibrosis , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease Patients poorly control hypertension multiple antihypertensives Karnofsky score &lt; 60 Lansky score &lt; 50 All patient receive antifungal therapy voriconazole , posaconazole , fluconazole must sirolimus reduce accord Standard Practice Antifungal Therapy Guidelines The addition cytotoxic agent `` cytoreduction '' exception tyrosine kinase inhibitor ( imatinib ) , cytokine therapy , hydroxyurea , low dose cytarabine , chlorambucil , Rituxan allow within three week initiation condition DONOR : Donor ( center ) exclusively donate marrow DONOR : Donors HIVpositive and/or , medical condition would result increase risk GCSF mobilization harvest PBSC DONOR : Patients homozygous mismatch HLA class I locus II locus , donor exclude homozygous mismatch locus ( i.e. , patient homozygous A*01:01 donor homozygous A*02:01 ) ; type mismatch consider twoantigen mismatch allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>